

C Louwrens Braal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8904828/publications.pdf>

Version: 2024-02-01

11
papers

249
citations

1683934

5
h-index

1372474

10
g-index

13
all docs

13
docs citations

13
times ranked

213
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 477-484.	2.3	4
2	Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. <i>Clinical Pharmacokinetics</i> , 2022, 61, 527-537.	1.6	17
3	Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 163-175.	1.1	3
4	Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210810.	1.4	2
5	Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation. <i>Hepatology Communications</i> , 2022, 6, 2565-2568.	2.0	1
6	Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 65-74.	1.1	6
7	Quantification of ribociclib in dried blood spots by LC-MS/MS: Method development and clinical validation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 201, 114118.	1.4	6
8	Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. <i>Drugs</i> , 2021, 81, 317-331.	4.9	173
9	Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 107-113.	1.1	14
10	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1980-1981.	0.8	18
11	Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 175-182.	1.4	5